Unlike chemotherapy, radioligand therapy's effectiveness wanes as tumors shrink. With less PSMA target for the drug to bind to, less radiation is delivered to the cancer. This physical reality supports "adaptive dosing"—stopping treatment in high-responders to spare healthy tissue and resume later if needed.
Medical oncologists are trained to treat continuously to eliminate micrometastatic disease. Radioligand therapy challenges this dogma, as its effectiveness is tied to target volume. As tumors shrink, the therapy becomes less potent against the cancer and relatively more toxic to healthy organs, requiring a mental shift to an adaptive, physics-based model.
Early in treatment, tumors are "target-rich" with high PSMA expression, creating an ideal window for radioligand therapy. Citing data from the VISION trial, new clinical trials are being designed to accelerate dosing and intensity upfront to maximize impact, then de-escalate as the target diminishes.
While Pluvicto (lutetium) is approved for six cycles, clinicians are retreating relapsed patients who previously responded well. This common practice occurs in a "data-free zone," driven by the lack of better options and the logic that a previously effective drug may work again in a patient selected for prior response.
Unlike traditional CT scans, PSMA-PET scans visualize the biological heterogeneity of prostate cancer, showing which lesions are target-rich and which are not. While insightful, this "shines a flashlight" on the problem, creating new clinical challenges, such as how to manage a patient whose disease largely disappears except for two resistant lesions.
The CCTG PR21 trial revealed a paradox: patients treated with lutetium first had a PSA response rate double that of docetaxel chemotherapy. However, overall survival was better for the group that received docetaxel first. This highlights the complexity of sequencing and suggests initial response isn't always predictive of long-term outcomes.
Despite two positive Phase 3 trials showing an overall survival benefit, Radium-223 is not widely used. A key reason is its failure to produce dramatic PSA declines or clear scan improvements. This lack of a satisfying, immediate feedback signal, or "firework display," makes clinicians less likely to prescribe it, even with proven efficacy.